Cara, Vi­for Phar­ma score speedy FDA nod on itch­ing drug for CKD — shares surge

The FDA has ap­proved Cara Ther­a­peu­tics and Vi­for Phar­ma’s Ko­r­su­va (dife­like­falin), a nov­el kap­pa opi­oid re­cep­tor ag­o­nist in­jec­tion to treat se­vere-to-mod­er­ate pru­ri­tis, or itch­ing, in pa­tients with chron­ic kid­ney dis­ease un­der­go­ing dial­y­sis, the com­pa­nies said Mon­day.

The part­ners ex­pect to launch in Q1, they said in a state­ment, and are cur­rent­ly as­sem­bling a re­im­burse­ment pack­age with the Cen­ters for Medicare and Med­ic­aid Ser­vices for sub­mis­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER